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Abstract 
Immune oncology treatment with immune checkpoint inhibitors (ICIs) is revolutionizing 
therapeutic approach for advanced non-small cell lung cancer (NSCLC) patients, in terms of 
longer survival and improved quality of life. To date, the widely used and approved 
biomarker is programmed death ligand 1 (PD-L1) expression on tumour cells, but it is 
considered not accurate and it is more likely that many factors, related to both cancer and 
host, may better predict response to ICI. Among those factors, great attention is being 
dedicated to tumour mutation burden, defined as the number of somatic non-synonymous 
mutations in cancer cells assessed with next-generation sequencing technologies. Moreover, 
recent evidences have shown that not only the quantity of tumour mutations, but also their 
quality may influence response to treatment with ICI. In fact, it seems that clonal 
heterogeneity of cancer cells, and of predicted neo-antigens, may affect anti-cancer 
response in patients receiving ICI. Our aim would be to report and discuss the available 
evidences on this topic along with the techniques used to assess clonal heterogeneity as a 
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biomarker that in future might help physicians to improve NSCLC patients’ selection for 
immune-oncology treatments. 
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1. Introduction 
Immune oncology treatment with immune checkpoint inhibitors (ICIs) is revolutionizing 
management of advanced non-small cell lung cancer (NSCLC) patients, a disease which still 
represents the leading cause of cancer mortality in both sexes [1]. 
Immune checkpoints like cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 
(PD-1) play a major role in T-cell activation and apoptosis, as well as in the maintenance of 
peripheral immune tolerance [2]. ICIs represent a novel class of anti-cancer agents that block 
these inhibitory T-cell receptors and consequentially, restore the immune system functionality in 
exerting an effective anti-tumor response.  
In non-oncogene addicted IV stage NSCLC, monoclonal antibodies directed against PD-1, 
nivolumab and pembrolizumab, or against programmed death ligand-1 (PD-L1), atezolizumab, 
have received accelerated approval for both first and further lines of therapy [3]. Whether 
nivolumab and atezolizumab can be given as second or further line of systemic treatment, 
irrespective of PD-L1 expression on tumour cells, pembrolizumab can be administered as first or 
further line of therapy, whenever PD-L1 expression is at least 50% or above 1%, respectively. All of 
the mentioned drugs have been approved only in monotherapy, however, based on the 
preliminary results from the phase III trial CheckMate 227, combination of nivolumab with the 
anti-CTLA4 agent ipilimumab has been included in the latest ESMO guidelines as an optional 
regimen [3]. Similarly, even though not yet formally approved by the European Medical Agency, 
ESMO guidelines recommend chemotherapy combined with pembrolizumab or atezolizumab as 
first line of treatment in patients with PD-L1 expression below 50%. 
2. Biomarkers of Response to ICI in Clinical Practice 
Despite ICIs clear success, benefit is not universal and the identification of both blood-based 
and tissue-based biomarkers is under investigation and constitutes a major research priority. As a 
matter of fact, PD-L1 expression, assessed with immunohistochemisty (IHC) on tumour specimens, 
is the only biomarker of response in clinical practice and presents several limitations. Besides the 
lack of standardization in PD-L1 IHC reading, evidences have shown that PD-L1 expression seems 
to be a weak biomarker of response to ICIs, especially in cases of low expression. Across all tumour 
types, response rates of 0-17% have been reported in patients with PD-L1-negative tumours 
receiving ICIs, whereas in PD-L1-positive tumours, response rates range from 36% to 100% [3, 4].  
To better investigate the mechanisms of response to ICIs, research has invested on alternative 
biomarkers, including those involved in neoantigen (neoAg) load. The term neoAg designate an 
immunogenic “non-self” peptide derived from tumour-specific DNA alterations, in contrast to 
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tumour antigens formed by non-mutated proteins with incomplete T self-tolerance due, in most 
cases, to restricted tissue expression pattern [5]. On a theoretical ground, neoAg load may predict 
response to ICI for the ability to chronically stimulate immune system, thus inducing T-cell 
exhaustion and PD-1 expression [6]. Therefore, also through innovative bioinformatics tools like 
next generation sequencing (NGS) technology, tumour mutational burden (TMB) rapidly entered 
the scenes of translational research. TMB, intended as the number of non-synonymous mutations 
within cancer genome, showed promising results in predicting response to ICI in early clinical data.  
Based on the preliminary results from Checkmate 227, the first phase III clinical trial to assess 
prospectively the role of TMB as a predictive biomarker, a combination of nivolumab plus 
ipilimumab has been recommended in patients with high TMB (> 10 mutations per megabase), by 
the ESMO guidelines, regardless of PD-L1 expression [3, 7]. However, this early recommendation 
should be read with caution, considering that the final analyses of this trial are still ongoing and, so 
far, the only available data refer to progression free survival rate in two of the three cohorts of the 
study [7]. In fact, beyond the enthusiasm arisen from clinical trials, many issues are still debated. A 
practical concern regards the most appropriate NGS platform to assess TMB and, as a 
consequence, the lack of a validated threshold. The first studies evidencing an association 
between high TMB and response to ICIs used whole-exome sequencing (WES) on tumour 
specimens [8, 9]. However, despite its proven utility, WES implies high costs and expertise, making 
it unrealistic to be used in routine clinical practice. Therefore, numerous targeted sequencing 
panels based on hybrid capture-based NGS have been developed and evaluated on both tumour 
tissue and blood retrospectively, suggesting that TMB may be a valuable tool in predicting ICI 
response [10, 11]. In this respect, it is worth to mention that the possibility to assess TMB on 
blood seems particularly advantageous: being a non-invasive technique, it allows longitudinal 
assessments to monitor tumour evolution along treatment, potentially allowing to gain a deeper 
insight into tumour heterogeneity. 
3. Neoantigen Prediction Models and Definition of Clonal Heterogeneity  
From a biological perspective, the main obstacle in considering TMB as a reliable predictive tool 
lies in its intrinsic “quantitative” nature, since basically it represents a surrogate for neoAg load. 
TMB does not take into account all the passages that go from a cancer gene mutation to the 
development of an immunogenic neoAg. Many variables may interfere with the induction of a 
viable T cell response: these variables are related to the type of neoAg produced, to the way the 
neoAg is processed and presented on the surface on the tumour cell and to the probability that it 
is bounded to a Human Leucocytes Antigen (HLA) class I molecule, which is an essential step for 
neoAg recognition by CD8 T cells. [5, 12]. 
Over the past decade, neoAg prediction models have been carried out using the now available 
bioinformatics predictive algorithms. These methods first apply NGS to identify expressed and 
coding mutations within tumour, then select candidate-mutated peptides that may derive from 
those coding mutations and finally predict which peptides more likely may be presented by HLA 
class I molecules [12]. To elicit an effective anti-cancer immune response, a further step beyond 
neoAg presentation is neoAg ability to be recognized as foreign (immunogenicity). Immunogenicity 
of an Ag depends on several factors, like the type of cancer cell mutation (non-synonymous single 
nucleotide variant vs indel variants) and the degree the protein product differs from the wild-type 
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counterpart, as well as the position of the mutated amino acid within the peptide. [13, 14]. 
Moreover, recent evidences have shown that also neoAg heterogeneity, intended as cancer 
mutation clonality, plays a role in inducing T-cell response in NSCLC patients, either spontaneously 
or after ICI administration. As a premise, the phenomenon of tumour heterogeneity and clonal 
evolution in NSCLC has been deeply investigated in 2 recent works based on multi-region 
sequencing of surgically resected lung cancers [15, 16]. These works defined three types of genetic 
alterations in lung tumours: “trunk” mutations, clonal, thus present in all regions of the tumour; 
“branches” mutations, heterogeneous, present only in some regions of the tumour and “private” 
mutations, present only in one tumour region. Under an evolutionary point of view, these 
different types of mutations reflect the temporal development of the tumour, with trunk 
mutations occurring at earlier stages than branch and private mutations.  
4. Clonal Heterogeneity as a Biomarker of Response to Immune Check-Point Inhibitors (ICIs) 
The impact of tumour heterogeneity on the prognosis of NSCLC patients has been first outlined 
by the study from De Bruin et al., reporting that patients with larger subpopulations of subclonal 
mutations in primary tumours relapsed earlier than those with a lower extent of subclonal disease 
[15]. The connection between clonal heterogeneity, cancer evasion from immune system and 
response to ICIs, has been extensively studied by the group of McGranahan. The first work 
addressing this issue analysed neoAgs expression in melanoma and lung cancer samples and 
monitored the clonal evolution of the tumour, observing that tumours with clonal expression of 
neoAgs showed an increased probability to respond to checkpoint blockade [17]. More in detail, in 
NSCLC patients, neoAg heterogeneity was studied in two types of samples, examined alternatively 
with multi-region or single sample sequencing. In both cases, the specimens more often pertained 
to early-stage disease. Multi-region sequence analysis was available for 7 primary cultures. In this 
case, each coding mutation detected was classified as clonal if ubiquitously present in every 
tumour region sequenced within the tumour. Conversely, any mutation present only in a fraction 
of the tumour regions sequenced was classified as subclonal. NeoAg and clonality analysis were 
then performed also on a larger cohort of NSCLC patients from The Cancer Genome Atlas dataset 
subjected to single sample sequencing. Here, clonal status was determined assessing the cancer 
cell fraction for each neoAg, intended as the proportion of cancer cells harbouring the 
corresponding mutation. 
Interestingly, in lung adenocarcinomas, neoAg load was found to be positively associated with 
tumour homogeneity and overall survival, independently from disease stage. This data was not 
confirmed in squamous cell carcinoma, despite a comparable number of predicted neoAgs. Thus, 
to shed light on this disparity, immune-regulatory genes expression was compared in the two 
histologies, evidencing a significant down-regulation of HLA molecules in the squamous cancer 
type. Other relevant finding was that, within the lung adenocarcinoma histotype, expression of 
PD-L1 and of the proinflammatory cytokine interleukin-6 (IL-6) was significantly higher in the 
homogeneous and high clonal neoAg group when compared to the more heterogeneous group. All 
the data strongly suggest that high clonal neoAg load is able to trigger a stronger T-cell response, 
as prompted by the presence of an inflamed microenvironment phenotype. As for response to ICI 
treatment, authors analyzed the clonal architecture of 34 NSCLC patients receiving 
pembrolizumab, and of those where WES data was available. Also in this case, both low tumour 
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heterogeneity and high mutational/neoAg load were positively related to PD-1 blockade efficacy 
with synergistic effect.  
Starting from the findings of this work, the same group carried out a study focused on HLA class 
I expression on NSCLC cells [18]. As mentioned above, HLA functionality in the presentation of 
tumour neoAg plays a key role in T-cell recognition and represents the main counterpart of TMB. 
Bioinformatics prediction of HLA class I status may enrich TMB role as a biomarker of response to 
ICI treatment. Using a computational tool permitting allele-specific copy number estimation of the 
HLA locus, called LOHHLA (loss of heterozygosity in human leukocyte antigen), the study 
evidenced that loss of heterozygosity (LOH) of the HLA locus occurs in 40% of early stage NSCLC. 
Moreover, HLA LOH, also reflecting in down-regulation, is associated with high subclonal neoAg 
burden and has been observed more often in metastatic sites rather than in primary tumours. 
These data suggest that HLA LOH is a mechanism of immune escape occurring at more advanced 
stages of tumour evolution after strong selection pressures. To corroborate this hypothesis, in 
both lung adenocarcinomas and lung squamous cell carcinomas, subclonal cells with HLA LOH 
were shown to have a significantly elevated non-synonymous mutation/neoAg burden and high 
level of PD-L1, indicating a pre-existing immunity. Therefore, in cells with immunogenic neoAgs, 
loss of HLA alleles may represent a late event of immune escape, contributing to subclonal 
expansions and treatment resistance.  
Looking at clonal heterogeneity in cancer from a different perspective, Jia et al.  focused on 
spatial intra-tumour immune heterogeneity, in a recent study. They define immune heterogeneity 
as an infiltrate composed of both tumour-promoting and tumour-suppressing immune cells. In this 
study, surgically removed biopsies of 15 NSCLC patients were deeply analyzed at multiple sites. 
Among other findings, heterogeneity in the immune cell infiltration was shown to correlate with 
intra-tumour mutation heterogeneity.This analysis was carried out following the findings on TMB, 
wherein TMB correlated with clonal expansion of T-cell but not with their cytotoxic activity [19]. 
From an evolutionary point of view, these data may suggest that high mutation heterogeneity and 
its accompanying mixed immune infiltrate (which may reflect a more exhausted 
microenvironment) may be events occurring at later stages of tumour development as a result of 
immune-editing, where cancer and immune cells are involved in a mutual and continuous reshape 
process.  
5. Future Perspectives 
In a future perspective, a further understanding of the onset of subclonal events, as well as of 
the selection pressure that drives it, would help to find smart strategies to manipulate it. The data 
discussed above, prompting for clonal heterogeneity to be a later event, may justify starting ICI 
therapy at earlier stages of the disease. However, future longitudinal studies to confirm these 
hypotheses are largely needed.  
To conclude, tumour clonal heterogeneity may represent one of the phenomena driving 
immune evasion in cancer. Thanks to the new technological and bioinformatics tools, in a near 
future, we expect to integrate biological data deriving from both the tumour and the host, with 
the final aims to better guide the selection of NSCLC patients who most likely will benefit from ICI 
treatment and to design tailored treatment approaches able to delay or prevent subclonal events, 
thus enhancing the anti-tumor effect of immune-oncology treatments.  
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